Showing 1341-1350 of 5603 results for "".
Double-Class Refractory CLL in Community Practice: Current and Future Management
https://reachmd.com/programs/cme/double-class-refractory-cll-in-community-practice-current-and-future-management/39261/Explore expert-guided strategies for managing double-class-refractory CLL, including BTK resistance, treatment sequencing, and emerging therapeutic options.Practical Perspectives in Myasthenia Gravis #2: Patient Stratification and Antibody Profiling—Personalizing the Disease Lens
https://reachmd.com/programs/cme/gmg-patient-stratification-and-antibody-profiling-personalizing-the-disease-lens/39029/Examine how antibody testing and patient characteristics inform personalized care when managing generalized myasthenia gravis.Emerging Evidence: IgAN Disease-Modifying Agents
https://reachmd.com/programs/cme/emerging-evidence-igan-disease-modifying-agents/54684/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Tailoring Treatment: Can You Select the Best Therapy?
https://reachmd.com/programs/cme/tailoring-treatment-can-you-select-the-best-therapy/51483/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
https://reachmd.com/programs/cme/rason-and-beyond-clinical-integration-and-strategic-sequencing/54124/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.From Data to Debate: Global Perspectives on HR+/HER2- mBC Care
https://reachmd.com/programs/cme/from-data-to-debate-global-perspectives-on-hrher2-mbc-care/37268/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
https://reachmd.com/programs/cme/distinguishing-first-line-treatment-adverse-event-profiles-in-her2-negative-upper-gi-cancers/37691/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingUnmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
https://reachmd.com/programs/cme/unmet-needs-in-endocrine-therapy-rethinking-the-hrher2-mbc-treatment-roadmap/39797/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Emerging Therapies in IgAN: Who Could Benefit the Most?
https://reachmd.com/programs/cme/emerging-therapies-in-igan-who-could-benefit-the-most/54685/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
https://reachmd.com/programs/cme/targeting-lower-proteinuria-levels-shifting-the-goalpost-in-igan/54686/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.